Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$33.72 - $47.33 $58,639 - $82,306
1,739 Added 1.47%
120,301 $5.41 Million
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $2.92 Million - $4.13 Million
118,562 New
118,562 $4.11 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.4B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.